Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Anniina Färkkilä(University of Helsinki), Panagiotis A. Konstantinopoulos(Dana-Farber Cancer Institute), Sandro Santagata(Harvard University), Connor A. Jacobson(Harvard University), Julia Casado(University of Helsinki), Peter J. Park(Harvard University), Zoltan Maliga(Harvard University), Sampsa Hautaniemi(University of Helsinki), Alan D. D’Andrea(Dana-Farber Cancer Institute), Geoffrey I. Shapiro(Brigham and Women's Hospital), Clarence Yapp(Harvard University), Ana Lako(Brigham and Women's Hospital), Ursula A. Matulonis(Dana-Farber Cancer Institute), Scott J. Rodig(Brigham and Women's Hospital), D. Gulhan(Harvard University), Peter K. Sorger(Harvard University Press), Elizabeth Garcia(Brigham and Women's Hospital), Denis Schapiro(Heidelberg University), Yu‐An Chen(Harvard University), Pamela N. Münster(University of California, San Francisco), Elizabeth M. Swisher(University of Washington), Bose Kochupurakkal(Brigham and Women's Hospital), Yinghui Zhou(Second Xiangya Hospital of Central South University), Julie R. Graham(Tesaro (United States)), Dipanjan Chowdhury(Broad Institute), Bruce J. Dezube(Xilio Therapeutics (United States)), Huy Nguyen(Dana-Farber Cancer Institute)
Nature Communications
May 18, 2020
Cited by 13


Related Papers